contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-indsender-cta-til-fase-1-forsog-af-utreat-i-patienter-med-aggressiv-hjernesvulst

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

Curasight: Indsender CTA til fase 1 forsøg af uTREAT i patienter med aggressiv hjernesvulst

Efter kapitalforh&#xf8;jelsen er kommet p&#xe5; plads indsendes CTA(Clinical Trial Application) som tidligere udmeldt p&#xe5; det vigtige Proof-of-Concept studie for uTREAT i Glioblastom eller aggressiv hjernesvulst. N&#xe5;r ans&#xf8;gningen er godkendt, sigter selskabet mod at levere en forel&#xf8;big afrapportering af del 1 af fase I/IIa-studiet i andet halv&#xe5;r af 2025, efterfulgt af endelige effektdata i f&#xf8;rste halv&#xe5;r af 2026.
Curasight A/S indsender ans&#xf8;gning om klinisk afpr&#xf8;vning for fase 1-studie med uTREAT&#xae; til patienter med hjernetumorer
<ul data-start="194" data-end="596">
<li data-start="194" data-end="347">
Indsendelsen af ans&#xf8;gningen om klinisk afpr&#xf8;vning markerer fremskridt i udviklingen af uTREAT&#xae; til behandling af aggressiv hjernesvulst (glioblastom)
</li>
<li data-start="348" data-end="421">
Glioblastom er den hyppigste d&#xf8;ds&#xe5;rsag blandt voksne med hjernesvulst
</li>
<li data-start="422" data-end="481">
F&#xf8;rste patient forventes doseret i andet halv&#xe5;r af 2025
</li>
<li data-start="482" data-end="596">
uTREAT repr&#xe6;senterer en potentiel ny behandlingsmulighed inden for et omr&#xe5;de med stort ud&#xe6;kket medicinsk behov
</li>
</ul>
Selskabet udsendte f&#xf8;lgende pressemeddelelse i g&#xe5;r efter b&#xf8;rsen lukkede - l&#xe6;s her: <a href="https://www.curasight.com/news/press-releases/2025/curasight-as-submits-clinical-trial-application-for-phase-1-trial-with-utreat-in-brain-cancer-patients/" target="_blank" rel="noopener">Curasight indsender CTA</a>
Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR abonnementsaftale. /Claus Thestrup kl. 8:20, 19/06/2025.